Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Standard chemotherapy regimen may increase survival rates in limited stage Hodgkin's lymphoma patients

New research led by the NCIC Clinical Trials Group (CTG) at Queen's University has proven patients with limited stage Hodgkin's lymphoma have a better chance of long-term survival if they undergo a standard chemotherapy regimen as opposed to radiation-based treatment.

14 Dec 2011

Scientists identify gene mutation behind Waldenstrom's macroglobulinemia

Scientists at Dana-Farber Cancer Institute have identified a gene mutation that underlies the vast majority of cases of Waldenstrom's macroglobulinemia, a rare form of lymphoma that has eluded all previous efforts to find a genetic cause.

13 Dec 2011

Plexxikon announces scientific findings from PLX3397 preclinical studies on AML

Plexxikon Inc., a member of Daiichi Sankyo Group, today announced scientific findings from preclinical studies showing that treatment with a novel oral agent, PLX3397, selectively inhibited key cancer-driving Flt3 mutations that occur in 20-30 percent of acute myeloid leukemia (AML) patients.

13 Dec 2011

Re-treatment with rituximab may benefit patients with LTB follicular lymphoma

Asymptomatic patients diagnosed with nonbulky follicular lymphoma, a slow-growing type of non-Hodgkin lymphoma, have traditionally been watched for signs or symptoms of disease progression and then treated with a combination of rituximab and chemotherapy or rituximab alone for select cases. Recent trials have suggested a role for treatment of asymptomatic patients with single-agent rituximab followed by additional periodic dosing, called "maintenance therapy."

12 Dec 2011

New findings from Micromet's blinatumomab phase 1 trial on DLBCL

New findings from a phase 1 trial presented yesterday at the 53rd Annual American Society of Hematology (ASH) Annual Meeting demonstrate Micromet's blinatumomab induces durable responses in patients with extensively pre-treated diffuse large B cell lymphoma.

12 Dec 2011

Syndax announces data from entinostat phase 2 study on HL

Syndax Pharmaceuticals, Inc. announced today that data from ENGAGE 501, a multicenter, phase 2 study, demonstrated entinostat, a novel, oral small molecule inhibitor of class I histone deacetylases, showed activity as a single agent in patients with relapsed or refractory Hodgkin's lymphoma.

12 Dec 2011

Breakthroughs in hematopoietic cell transplantation to be presented at 53rd ASH meeting

Hematopoietic cell transplantation (HCT), the transplantation of blood-forming stem cells from the bone marrow, peripheral blood, or umbilical cord blood, is the primary option for treatment for many patients who suffer from various hematologic disorders, including blood cancers, sickle cell disease, bone marrow deficiencies, bleeding disorders, and autoimmune disorders. Research investigating breakthroughs in hematopoietic cell transplantation will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

People in Northern Ireland less likely to develop cancers

People in Northern Ireland have a lower risk of developing some cancers than those living in the Republic of Ireland, according to the All-Ireland Cancer Atlas - a collaborative publication by the Northern Ireland Cancer Registry at Queen's University Belfast and the National Cancer Registry in Cork.

12 Dec 2011

FDA assigns CTIs' pixantrone NDA new PDUFA action date

Cell Therapeutics, Inc. today announced that the U.S. Food and Drug Administration's Division of Oncology Products 1 has notified CTI that CTI's October 2011 resubmitted New Drug Application is considered a complete, Class 2 response to the FDA's April 2010 complete response letter.

6 Dec 2011

CTI seeks license to market Pixuvri in the E.U. for treatment of NHL

Cell Therapeutics, Inc. announced today an update on the status and progress of its European marketing authorization application for Pixuvri.

5 Dec 2011

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

Treatments for lymphoma with no side effects

Larry Conrad went in for his annual physical on his 50th birthday. During his exam, his doctor found swollen lymph nodes in his armpits and groin. Conrad had a cough and said he'd lost weight because he 'felt full all the time'. His doctor ordered a series of tests, and Conrad was diagnosed with Non-Hodgkin's lymphoma, the most common type.

2 Dec 2011

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

The American Society of Hematology (ASH) recognizes the following abstract presenters at the 53rd ASH annual meeting in San Diego, CA, with the highest scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow.

2 Dec 2011

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

The John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 31 cutting-edge studies at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego from December 10-13.

2 Dec 2011

Study reveals underlying molecular mechanism contributing to development of lymphomagenesis

Researchers from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, have discovered a new potential therapeutic target for Diffuse Large B-Cell Lymphoma (DLBCL), the most aggressive and common type of lymphoma in adults.

29 Nov 2011

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) on November 18, 2011 to remove the pre-treatment biodistribution evaluation requirement using Indium-111 ZEVALIN imaging dose followed by a gamma scan before administering the ZEVALIN therapeutic dose.

21 Nov 2011

New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting

Pfizer Oncology will present data on a number of investigational compounds from its hematology portfolio, including new data from bosutinib in chronic myeloid leukemia (CML), inotuzumab in non-Hodgkin lymphoma (NHL), as well as the first presentation of clinical data for PF-04449913, which inhibits Smoothened (SMO), a key component of the Hedgehog pathway.

7 Nov 2011

Pharmacyclics first quarter GAAP net loss increases to $14.5M

Pharmacyclics, Inc. today reported financial results and recent developments for its fiscal first quarter ended September 30, 2011.

7 Nov 2011

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is proud to sponsor several key sets of Cimzia (certolizumab pegol) data at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, November 5-9.

7 Nov 2011

EBV vaccine could prevent mononucleosis and cancers linked to virus

In a new article from the National Institutes of Health (NIH), Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), and Harold Varmus, M.D., director of the National Cancer Institute (NCI), join Gary Nabel, M.D., Ph.D., director of NIAID's Vaccine Research Center, and Jeffrey Cohen, M.D., chief of NIAID's Laboratory of Infectious Diseases, in summarizing a recent meeting of experts who gathered to map directions toward an EBV vaccine.

3 Nov 2011